


TDM Kit System in brief

Antiepileptic Drugs in Serum/Plasma



Antiepileptic Drugs

The "ClinMass® TDM Kit System is based on a universal TDM Platform (order no. MS9000), which can be used with various Add-on Sets for the Therapeutic Drug Monitoring (TDM).

The ClinMass® Add-on Set for Antiepileptic Drugs (order no. MS9200) is intended for the determination of antiepileptic drugs from human serum or plasma.

- + Identification of steady-state conditions
- + monitoring of parent compound/active metabolites

Therapeutic Drug Monitoring (TDM)

Increasing recommendation in

- + conditions with a small therapeutic range
- optimisation of a personalised pharmacotherapy
- + monitoring the effective therapy regime
- + detection of drug/drug interactions
- + toxicity avoidance
- + monitoring of patient's compliance



The use of the RECIPE Kit System requires an LC system with tandem mass spectrometer (LC-MS/MS) with sufficient sensitivity and evaluation software.





Clinical Background

Epilepsy is a chronic neurological disorder, characterised by recurrent epileptic seizures. The frequency and the rhythm of seizures are hardly predictable. Therefore, seizures are not only a considerable psychological and physical burden for the patient, they may also lead to grave and even lifethreatening hurts (e.g. craniocerebral injuries in case of falls). Brain damages may result in case of a hypoxia. Today, a variety of antiepileptic drugs (AEDs) with different pharmacological properties is available.

Therapeutic drug monitoring (TDM) is the clinical laboratory practice to determine drug concentrations in blood to optimise a personalised pharmacotherapy, especially in indications with a small therapeutic range. Drug interactions, efficacy, toxicity avoidance and the surveillance of compliance are typical indications where TDM is requested.

The RECIPE analytical method provides the reliable quantification of 27 AEDs.




Figure 1 Chromatogram of the ClinCal® Serum Calibrator (order no. MS9213), level 2





Method Performance

The interassay precision of the method was determined with samples at two concentration levels. The samples were prepared by different persons on eight different days and measured on several systems from different manufacturers (for data from a specific system please contact info@recipe.de). The analyte concentrations were selected according to the respective therapeutic reference range and are contained in Table 2 together with the precision results.

	Concentration		Intraassay Precision		Interassay Precision	
	[mg/I]		[%]		[%]	
Analyte	Level		Level		Level	
	1	П	I	II	l	II
10-OH-Carbamazepine	2.80	42.9	2.3	3.1	8.3	2.9
Brivaracetam	0.300	4.25	1.7	2.9	4.6	5.9
Carbamazepine	2.66	16.4	2.1	2.0	4.8	5.7
Carbamazepine-Diol	0.889	5.20	1.8	1.7	10.3	10.6
Carbamazepine-Epoxide	1.40	8.27	1.5	2.3	11.6	10.7
Ethosuximide	19.0	93.6	3.2	3.8	5.9	5.8
Felbamate	19.6	45.8	2.1	2.0	5.0	9.2
Gabapentine	1.87	27.8	5.2	2.7	8.4	3.2
Lacosamide	3.91	11.2	0.8	2.2	5.0	4.0
Lamotrigine	2.92	13.9	1.2	2.6	5.9	2.7
Levetiracetam	9.54	23.5	0.7	1.9	5.1	7.2
NDMS	9.48	53.6	3.3	1.3	9.0	7.9
Oxcarbazepine	1.43	5.97	6.6	4.4	8.8	9.8
PEMA	4.63	25.7	2.2	1.8	3.4	4.5
Perampanel	0.0974	1.46	2.8	3.2	9.1	8.5
Phenobarbital	9.17	53.0	2.1	1.5	4.4	4.6
Phenytoine	1.94	28.3	3.5	6.6	4.2	3.3
Pregabaline	1.83	6.16	1.6	2.2	8.8	5.0
Primidone	4.39	25.1	4.5	2.2	2.2	5.5
Retigabine	0.514	0.969	1.2	2.4	4.3	5.1
Rufinamide	3.11	47.4	2.1	4.0	8.3	6.1
Stiripentol	3.85	10.9	2.3	2.9	7.6	9.3
Sulthiame	0.946	12.7	4.5	3.6	8.3	5.9
Tiagabine	47.0	132	1.6	2.2	6.7	6.9
Topiramate	2.79	8.93	1.5	2.6	8.7	7.5
Valproic acid	21.3	125	2.4	1.2	5.0	7.7
Zonisamide	9.49	21.7	2.4	1.7	6.8	7.8

Table 2. Method Performance/Precision data





Reference ranges

The following reference ranges are taken from the "Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017"

Analyte	Therapeutic Range	Laboratory Alert Level [†]		
	[mg/l]	[mg/l]		
Brivaracetam	0.5–0.9	1.8		
Oxcarbazepine plus	10–35	40		
10-OH-Carbamazepine				
Carbamazepine	Mood stabilizing drug: 4–10	Mood stabilizing drug: 20		
	Anticonvulsant: 4–12	Anticonvulsant: 20		
Carbamazepine-Diol	n.a.	n.a.		
Carbamazepine-Epoxide	n.a.	n.a.		
Ethosuximide	40–100	120		
Felbamate	30–80	100		
Gabapentine	2–20	25		
Lacosamide	1–10	20		
Lamotrigine	Mood stabilizing drug: 1–6	Mood stabilizing drug: 20		
	Anticonvulsant: 3–15	Anticonvulsant: 20		
Levetiracetam	10–40	50		
Methsuximid plus	10–40	45		
NDMS	10–40	45		
PEMA	n.a.	n.a.		
Perampanel	0.18-0.98	1		
Phenobarbital	10–40	50		
Phenytoin	10–20	25		
Pregabaline	Anticonvulsant: 2–5	Anticonvulsant: 10		
	Anxiolytic: 2–5	Anxiolytic: 10		
Primidone	5–10	25		
Retigabine	0.45-0.90	1.8		
Rufinamide	5–30	40		
Stiripentol	1–10	15		
Sulthiame	2–8	12		
Tiagabine	0.02-0.2	0.3		
Topiramate	2–10	16		
Valproic acid	Mood stabilizing drug: 50–100	Mood stabilizing drug: 120		
	Anticonvulsant: 50–100	Anticonvulsant: 120		
Zonisamide	10–40	40		

Table 3: Reference ranges n.a.: not available; †at values above the "Alert level" the physician in charge should be informed immediately

The indicated reference ranges are taken from thoroughly selected and current scientific literature. Their actuality corresponds to the printing date of this document. Please note that these ranges do not reflect any recommendations by the manufacturer of this product, but may be used as a guideline for the assessment of the reference range by the clinical laboratory.

5

Conclusion

The RECIPE 200 TDM Kit

- ✓ improves the individual therapeutic regimen for the patient
- √ adopts fast growing medical need by regular addition of new drug classes
- √ is validated, no new validation is necessary
- √ offers you a flexible expansion of the add-on sets



Chemicals + Instruments GmbH Dessauerstr. 3 80992 München

Mail: info@recipe.de